Kovalizumab price information and purchasing guide

Crovalimab, an innovative biologic, is indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients 13 years of age and older and weighing at least 40 kg. PNH is a rare and serious blood disease. The launch of kovalizumab brings new treatment hope to these patients.

On February 6, 2024, China's State Food and Drug Administration approved the marketing application for kovarizumab injection, with the trade name of Pasika. This is also the first time this drug has been approved globally. Subsequently, in June of the same year, the United States also approved its marketing, further proving the effectiveness and safety of kovarizumab in the treatment of PNH.

However, due to its relatively short time on the market, kovalizumab has not yet been included in my country's medical insurance system. Therefore, its price is not yet clear and may be affected by various factors such as sales channels, regions, and medical insurance policies, resulting in fluctuations in the actual price. Patients need to fully understand these factors when purchasing in order to make reasonable decisions.

In terms of purchase method, patients can purchase through regular medical consultation institutions or pharmacies. Since corvalizumab is a prescription drug, patients need to use it under the guidance of a doctor, so a doctor's prescription is required when purchasing. At the same time, in order to ensure the quality and safety of drugs, patients should avoid purchasing drugs through informal channels.
It is worth noting that with the continuous promotion and deepening of kovarizumab's clinical application, its price may gradually stabilize in the future, and it is expected to be included in the medical insurance system, thus reducing the financial burden on patients. In addition, patients can also pay attention to relevant medical assistance projects to obtain more financial support.
In short, it is very important for patients who need to use kovalizumab to understand the price information and how to purchase it. Patients should choose the most appropriate purchase method under the guidance of their doctor, combined with their own financial situation and needs, and ensure the quality and safety of the medicine.
Reference link: https://www.accessdata.fda.gov/drugsatfda docs/label/2024/761388s000lbl.pdf